Open Access Open Access  Restricted Access Subscription or Fee Access

From the publisher

Richard A. DeVito, Jr.

Abstract


Those words don’t quite cover the time and dedication that our two special issue editors have invested in our Journal of Opioid Management special issue–Buprenorphine: Clinical and Public Policy Implications. From the beginning, Mary Lynn McPherson, PharmD, MA, MDE, BCPS, CPE and Mellar P. Davis, MD, FCCP, FAACP have been “all in” lending their expertise and wisdom to create a simply outstanding special issue. The countless emails, reviews and advice are greatly appreciated. Truth be told, we are fortunate to have had their sage wisdom and support going back many years across many projects and 8 conferences! Thank you!


Keywords


buprenorphine, sustained-release

Full Text:

PDF

References


CDC Guideline for Prescribing Opioids for Chronic Pain-United States, www.cdc.gov.

Raiuck RL, Potts J, Xiang Q, et al.: Efficacy and tolerability of buccal buprenorphine in opioid-naive patients with moderate to severe chronic low-back pain. Postgraduate Medicine. 2016; 128(1): 1-11.

Howard RL, Avery AJ, Slavenburg S, et al.: Which drugs cause preventable admissions to hospital? A systematic review. Br J Clin Pharmacol. 2007 Feb; 63(2): 136-147.

Sultana J, Cutroneo P, Trifiro G: Clinical and economic burden of adverse drug reactions. J Pharmacol Pharmacother. 2013 Dec; 4(suppl): S73-S77.

Pirmohomad M, James S, Meakun S, et al.: Adverse drug reactions as cause of admission to hospital: prospective analysis of 18820 patients. BMJ. 2004: July 3; 329(7456): 15-19.

European Monitoring Center for Drugs and Drug Addiction: Selected Issues. 2005. Luxumbourg. Office for Official Publications of the European Communities. 1-45.

Wood E, Laga DL, Klimas J: Pain Management with Opioids in 2019-2020. JAMA. 2019; 322(19): 1914-1915.




DOI: https://doi.org/10.5055/jom.2021.0657

Refbacks

  • There are currently no refbacks.